Orphan-drug designation for Nav1.7 blocking pain drug CNV1014802 granted

Convergence Pharmaceuticals Limited, is pleased to announce that its novel sodium channel blocker, CNV1014802 , has been granted orphan-drug designation* by the US Food and Drug Administration for the treatment of trigeminal neuralgia .

http://www.medilexicon.com/medicalnews.php?newsid=264108